Format

Send to

Choose Destination
See comment in PubMed Commons below
Audiol Neurootol. 2011;16(6):388-97. doi: 10.1159/000322641. Epub 2011 Jan 21.

Safety of intratympanic injection of AM-101 in patients with acute inner ear tinnitus.

Author information

1
Department of ENT, Head and Neck Surgery, German Armed Forces Hospital Ulm, Ulm, Germany. gment @ t-online.de

Abstract

Effective pharmacological treatments for tinnitus have proven elusive. Emerging evidence suggests that dysregulation of cochlear N-methyl-D-aspartate (NMDA) receptors may underlie aberrant excitation of the auditory nerve, which in turn is perceived as tinnitus. The blocking of these receptors thus represents a promising therapeutic approach. In a recent phase I/II clinical trial, the safety and local tolerance of intratympanic injections of the NMDA receptor antagonist AM-101 was evaluated for the first time in humans. The results from the double-blind, randomized, placebo-controlled study show that intratympanically injected AM-101 was well tolerated by study participants, and provided the first indications of therapeutic efficacy.

PMID:
21252501
DOI:
10.1159/000322641
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Support Center